iBio (IBIO) Non-Current Assets (2011 - 2026)
iBio (IBIO) posted quarterly Non-Current Assets of $8.6 million for Q1 2026, down 34.19% year-over-year from $13.0 million in Q1 2025, and down 21.92% quarter-over-quarter from $11.0 million in Q4 2025.
iBio (IBIO) Non-Current Assets (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Non-Current Assets for 16 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 34.19% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $46.4 million (down 11.35% YoY), while the FY2025 annual figure was $13.5 million, up 3.08% from the prior year.
- Non-Current Assets eased to $8.6 million in Q1 2026 per IBIO's latest filing, from $11.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $55.1 million in Q1 2022 and bottomed at $8.6 million in Q1 2026.
- Historically, Non-Current Assets has averaged $18.7 million across 5 years, with a median of $13.6 million in 2022.
- On a YoY basis, Non-Current Assets climbed as much as 55.11% in 2022 and fell as far as 76.99% in 2022.
- iBio's Non-Current Assets stood at $13.6 million in 2022, then grew by 5.59% to $14.3 million in 2023, then fell by 6.36% to $13.4 million in 2024, then decreased by 18.04% to $11.0 million in 2025, then slipped by 21.92% to $8.6 million in 2026.
- Business Quant data shows IBIO's Non-Current Assets at $8.6 million in Q1 2026, $11.0 million in Q4 2025, and $13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | iBio | 172.82 Mn | 172.82 Mn | - | 8.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.58 Mn |
| Dec 31, 2025 | 10.99 Mn |
| Sep 30, 2025 | 13.36 Mn |
| Jun 30, 2025 | 13.46 Mn |
| Mar 31, 2025 | 13.04 Mn |
| Dec 31, 2024 | 13.41 Mn |
| Sep 30, 2024 | 12.82 Mn |
| Jun 30, 2024 | 13.06 Mn |
| Mar 31, 2024 | 14.02 Mn |
| Dec 31, 2023 | 14.32 Mn |
| Sep 30, 2023 | 14.66 Mn |
| Jun 30, 2023 | 14.95 Mn |
| Mar 31, 2023 | 17.29 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Sep 30, 2022 | 21.00 Mn |
| Jun 30, 2022 | 54.34 Mn |
| Mar 31, 2022 | 55.05 Mn |
| Dec 31, 2021 | 58.95 Mn |
| Sep 30, 2021 | 53.92 Mn |
| Jun 30, 2021 | 42.37 Mn |